Table 1.
A summary of the characteristics of the patients analyzed.
| Number | Gender/age | KPSa | Histology | Tumor size (mm) | Antiepileptic drug | Location |
|---|---|---|---|---|---|---|
| 1 | Mb/19 | 100 | Oligodendroglioma-II | 53 × 45 | Sodium valproate | LTd |
| 2 | Fc/22 | 100 | Oligodendroglioma-II | 42 × 31 | Sodium valproate | LFe |
| 3 | M/35 | 100 | Oligodendroglioma-II | 37 × 30 | Sodium valproate | LT |
| 4 | M/53 | 95 | Oligodendroglioma-II | 58 × 46 | Sodium valproate | LT |
| 5 | F/41 | 100 | Oligodendroglioma-II | 38 × 32 | Sodium valproate | LF |
| 6 | F/42 | 100 | Oligodendroglioma-II | 35 × 33 | Sodium valproate | LF |
| 7 | F/25 | 100 | Oligodendroglioma-II | 45 × 23 | Sodium valproate | LT |
| 8 | F/26 | 90 | Oligodendroglioma-II | 55 × 46 | Sodium valproate | RPf |
| 9 | M/36 | 100 | Oligodendroglioma-II | 64 × 65 | Sodium valproate | LF |
| 10 | F/54 | 100 | Oligodendroglioma-II | 48 × 43 | Sodium valproate | LF |
a: Karnofsky performance status; b: Male; c: Female; d: Left temporal; e: Left frontal; f: Right parietal. It has been added.